Bernier Virginie, Bichet Daniel G, Bouvier Michel
Département de Biochimie and Groupe de Recherche sur le Système Nerveux Autonome, Université de Montréal, Montréal, Québec, Canada H3C 3J7.
Curr Opin Pharmacol. 2004 Oct;4(5):528-33. doi: 10.1016/j.coph.2004.08.001.
An increasing number of genetic diseases are found to result from mutations that lead to retention of the affected proteins in the endoplasmic reticulum, where they are recognized as misfolded by the quality control system. Several of these conformational diseases involve mutations in G-protein-coupled receptors. Recent studies demonstrated that pharmacologically selective compounds, termed pharmacological chaperones, can stabilize the misfolded receptors, facilitating their export from the endoplasmic reticulum to the plasma membrane, where they can be active. Such functional rescue suggests that pharmacological chaperones could represent novel therapeutic agents for the treatment of conformational diseases. Although only a few examples are currently available, the observation that pharmacological chaperones can also favour the folding of wild-type G-protein-coupled receptors indicates that these compounds could have wide applications.
越来越多的遗传疾病被发现是由突变导致的,这些突变使得受影响的蛋白质滞留在内质网中,在内质网中它们被质量控制系统识别为错误折叠。其中几种构象疾病涉及G蛋白偶联受体的突变。最近的研究表明,被称为药理伴侣的药理学选择性化合物可以稳定错误折叠的受体,促进它们从内质网转运到质膜,在质膜上它们可以发挥活性。这种功能挽救表明药理伴侣可能代表治疗构象疾病的新型治疗药物。虽然目前只有少数例子,但药理伴侣也能促进野生型G蛋白偶联受体折叠这一观察结果表明,这些化合物可能有广泛的应用。